<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and regulatory body approved therapies. In particular, the current coronavirus" exact="disease" post="2019 (COVID-19) pandemic has quickly intensified interest in developing"/>
 <result pre="in potential therapeutic options for HCoV-related illnesses. In 2002â€&quot;2003, severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) infected more than 8000 people,"/>
 <result pre="potential therapeutic options for HCoV-related illnesses. In 2002â€&quot;2003, severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) infected more than 8000 people, reaching"/>
 <result pre="therapeutic options for HCoV-related illnesses. In 2002â€&quot;2003, severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) infected more than 8000 people, reaching 26"/>
 <result pre="2012 and November 2019, there were 2494 laboratory-confirmed cases of" exact="infection" post="with Middle East respiratory syndrome coronavirus (MERS-CoV) that reached"/>
 <result pre="there were 2494 laboratory-confirmed cases of infection with Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) that reached 27 countries and had"/>
 <result pre="were 2494 laboratory-confirmed cases of infection with Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) that reached 27 countries and had a"/>
 <result pre="have been underestimated [5]. Most recently, the emergence of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in"/>
 <result pre="been underestimated [5]. Most recently, the emergence of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan"/>
 <result pre="underestimated [5]. Most recently, the emergence of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan and"/>
 <result pre="intense interest in vaccine development and treatment options for coronavirus" exact="disease" post="2019 (COVID-19) [6,7]. Remdesivir (GS-5734, Fig. 1a) is an"/>
 <result pre="MERS-CoV, and strains of bat coronaviruses capable of infecting human" exact="respiratory" post="epithelial cells), Paramyxoviridae (such as Nipah virus, respiratory syncytial"/>
 <result pre="and strains of bat coronaviruses capable of infecting human respiratory" exact="epithelial" post="cells), Paramyxoviridae (such as Nipah virus, respiratory syncytial virus,"/>
 <result pre="infecting human respiratory epithelial cells), Paramyxoviridae (such as Nipah virus," exact="respiratory" post="syncytial virus, and Hendra virus), and Filoviridae (such as"/>
 <result pre="[[8], [9], [10], [11], [12]]. Originally developed to treat Ebola" exact="virus infection" post="[8], remdesivir is a prodrug of the parent adenosine"/>
 <result pre="[9], [10], [11], [12]]. Originally developed to treat Ebola virus" exact="infection" post="[8], remdesivir is a prodrug of the parent adenosine"/>
 <result pre="has displayed antiviral activity against SARS-CoV, Marburg virus, and feline" exact="infectious" post="peritonitis virus, among others [9,[14], [15], [16]]. A number"/>
 <result pre="displayed antiviral activity against SARS-CoV, Marburg virus, and feline infectious" exact="peritonitis" post="virus, among others [9,[14], [15], [16]]. A number of"/>
 <result pre="known as the second most prevalent cause of colds and" exact="upper" post="respiratory infections (URIs), after rhinoviruses [2,29]. The endemic human"/>
 <result pre="as the second most prevalent cause of colds and upper" exact="respiratory" post="infections (URIs), after rhinoviruses [2,29]. The endemic human CoVs"/>
 <result pre="the second most prevalent cause of colds and upper respiratory" exact="infections" post="(URIs), after rhinoviruses [2,29]. The endemic human CoVs that"/>
 <result pre="but a substantial proportion of these hospitalized patients had underlying" exact="pulmonary" post="or cardiac comorbidities that may have exacerbated their conditions"/>
 <result pre="nucleoside analog, remdesivir acts as an RdRp inhibitor, targeting the" exact="viral" post="genome replication process. The RdRp is the protein complex"/>
 <result pre="to many of these drugs, remdesivir seems to outpace this" exact="viral" post="proofreading activity, thus maintaining antiviral activity [30]. Unsurprisingly, Agostini"/>
 <result pre="[30]. Unsurprisingly, Agostini et al. reported that a mutant murine" exact="hepatitis" post="virus (MHV) devoid of proofreading ability was more sensitive"/>
 <result pre="yet to be discovered, which, if true, may allow for" exact="partial" post="antiviral activity to continue despite viral mutations that enhance"/>
 <result pre="true, may allow for partial antiviral activity to continue despite" exact="viral" post="mutations that enhance replication fidelity [[11], [12], [13]]. 4"/>
 <result pre="genetic diversity is posited to be attributable to the large" exact="viral" post="genome and the molecular nuances of the viral RNA"/>
 <result pre="the large viral genome and the molecular nuances of the" exact="viral" post="RNA replication processes (e.g., RdRp infidelity) [21]. Although remdesivir"/>
 <result pre="are hampered by the possibility that the drug may have" exact="secondary" post="mechanisms of action that are yet to be elucidated."/>
 <result pre="the peak inhibiting effect of the drug against a specific" exact="viral" post="function is achieved. Lower EC50 and IC50 values indicate"/>
 <result pre="Typical outcomes measured in such studies include the amount of" exact="viral" post="RNA (e.g., copies of certain open reading frames) in"/>
 <result pre="number of virus-infected cells in the culture, or changes in" exact="viral" post="replication rates. Table 1 Summary of in vitro studies"/>
 <result pre="Î¼M MHVâ€ DBT EC50Â =Â 1.1Â Î¼M â�ŽCalu-3: human bronchial" exact="epithelial" post="cells; HAE: human airway epithelial cells; DBT: mouse delayed"/>
 <result pre="1.1Â Î¼M â�ŽCalu-3: human bronchial epithelial cells; HAE: human airway" exact="epithelial" post="cells; DBT: mouse delayed brain tumor; Huh7: human liver"/>
 <result pre="epithelial cells; HAE: human airway epithelial cells; DBT: mouse delayed" exact="brain tumor;" post="Huh7: human liver cells; LLC-PK1: porcine kidney cells; Vero"/>
 <result pre="Huh7: human liver cells; LLC-PK1: porcine kidney cells; Vero E6:" exact="African" post="green monkey kidney epithelial cells; CRFK: feline kidney cells."/>
 <result pre="LLC-PK1: porcine kidney cells; Vero E6: African green monkey kidney" exact="epithelial" post="cells; CRFK: feline kidney cells. â�Žâ�ŽEC50Â =Â Half maximal"/>
 <result pre="as reported by each respective study. â€ MHVÂ =Â murine" exact="hepatitis" post="virus. â€¡PDCoVÂ =Â porcine deltacoronavirus. Â¥FIPVÂ =Â feline infectious"/>
 <result pre="murine hepatitis virus. â€¡PDCoVÂ =Â porcine deltacoronavirus. Â¥FIPVÂ =Â feline" exact="infectious" post="peritonitis virus. In studies of SARS-CoV and MERS-CoV in"/>
 <result pre="hepatitis virus. â€¡PDCoVÂ =Â porcine deltacoronavirus. Â¥FIPVÂ =Â feline infectious" exact="peritonitis" post="virus. In studies of SARS-CoV and MERS-CoV in human"/>
 <result pre="peritonitis virus. In studies of SARS-CoV and MERS-CoV in human" exact="respiratory" post="epithelial cell cultures, remdesivir has demonstrated strong antiviral activity"/>
 <result pre="virus. In studies of SARS-CoV and MERS-CoV in human respiratory" exact="epithelial" post="cell cultures, remdesivir has demonstrated strong antiviral activity (EC50Â"/>
 <result pre="This study investigated the impact of seven different drugs on" exact="viral" post="titers, cytotoxicity, and infection rates, using Vero E6 cells"/>
 <result pre="impact of seven different drugs on viral titers, cytotoxicity, and" exact="infection" post="rates, using Vero E6 cells (a cell line originating"/>
 <result pre="rates, using Vero E6 cells (a cell line originating from" exact="African" post="green monkey kidney epithelial cells). They found low potency"/>
 <result pre="cells (a cell line originating from African green monkey kidney" exact="epithelial" post="cells). They found low potency of most of these"/>
 <result pre="the two drugs that required the lowest concentrations for blocking" exact="viral infection." post="A few in vitro studies have also investigated the"/>
 <result pre="alphacoronavirus that only infects wild and domestic cats, the feline" exact="infectious" post="peritonitis (FIP) virus (EC50Â =Â 0.78Â Î¼M; Table 1)"/>
 <result pre="that only infects wild and domestic cats, the feline infectious" exact="peritonitis" post="(FIP) virus (EC50Â =Â 0.78Â Î¼M; Table 1) [14]."/>
 <result pre="Therefore, it was important to attempt to disentangle whether the" exact="lower" post="antiviral activity observed could be related to a viral"/>
 <result pre="the lower antiviral activity observed could be related to a" exact="viral" post="characteristic of PDCoV or if it could be attributable"/>
 <result pre="remdesivir against PDCoV was noted in cultures of porcine kidney" exact="epithelial" post="cells (LLC-PK1), in a human liver cell line (Huh7),"/>
 <result pre="compared to 0.02Â Î¼M in Huh7), again indicating the likely" exact="lower" post="potency of the drug in this context. Thus, the"/>
 <result pre="associated pathology, generally resulting in less lung damage and better" exact="pulmonary" post="function compared to controls [10]. Interestingly, among mice that"/>
 <result pre="more plaque-forming units), those receiving prophylactic remdesivir one day before" exact="infection" post="had significantly better 6-day survival than infected control mice"/>
 <result pre="prophylactic and therapeutic administration of remdesivir demonstrated favorable results, reducing" exact="respiratory" post="tract viral titers and pulmonary pathology [18]. Prophylactic use"/>
 <result pre="therapeutic administration of remdesivir demonstrated favorable results, reducing respiratory tract" exact="viral" post="titers and pulmonary pathology [18]. Prophylactic use was initiated"/>
 <result pre="remdesivir demonstrated favorable results, reducing respiratory tract viral titers and" exact="pulmonary" post="pathology [18]. Prophylactic use was initiated 24Â h prior"/>
 <result pre="pathology [18]. Prophylactic use was initiated 24Â h prior to" exact="viral" post="challenge, whereas therapeutic use was initiated 12Â h after"/>
 <result pre="whereas therapeutic use was initiated 12Â h after challenge. While" exact="respiratory" post="rate was not substantially different between the prophylactic, therapeutic,"/>
 <result pre="therapeutic, and control groups, x-ray scores, representing the severity of" exact="pulmonary" post="infiltrates, were significantly better in the prophylactic and therapeutic"/>
 <result pre="also been associated with beneficial effects, including reduced severity of" exact="respiratory" post="signs and improved survival, against challenge with Nipah virus,"/>
 <result pre="which is a non-CoV virus in the Paramyxoviridae family, in" exact="African" post="green monkeys [21]. In a Ces1c-knockout mouse model of"/>
 <result pre="of SARS-CoV infection, prophylactic and therapeutic remdesivir treatment resulted in" exact="lower" post="lung viral titers, and if therapy was administered 1Â"/>
 <result pre="infection, prophylactic and therapeutic remdesivir treatment resulted in lower lung" exact="viral" post="titers, and if therapy was administered 1Â day post-infection"/>
 <result pre="therapy was administered 1Â day post-infection (which is before peak" exact="viral" post="replication), it was associated with greater pulmonary function, compared"/>
 <result pre="is before peak viral replication), it was associated with greater" exact="pulmonary" post="function, compared to controls [11]. However, there were no"/>
 <result pre="compared to controls [11]. However, there were no differences in" exact="disease" post="pathology or survival if treatment was administered 2Â days"/>
 <result pre="potential utility in veterinary indications [35]. Subsequently, GS-441524 became an" exact="intermediate" post="in the production of the prodrug, remdesivir, which has"/>
 <result pre="(nÂ =Â 5) were treated with 2Â mg/kg daily. If" exact="disease" post="recurred after initial treatment, cats were re-treated using the"/>
 <result pre="post infection. Two cats (one from each dose group) experienced" exact="disease" post="recurrence at 4Â weeks and 6Â weeks after initial"/>
 <result pre="were re-treated. Adverse events related to treatment, other than temporary" exact="discomfort" post="at the injection site, were not observed. This study"/>
 <result pre="small number of animals, and it is unclear whether experimental" exact="infection" post="is a relevant representation of naturally-occurring FIPV infection in"/>
 <result pre="whether experimental infection is a relevant representation of naturally-occurring FIPV" exact="infection" post="in cats. Future studies with additional follow-up time would"/>
 <result pre="the first week of treatment, 4 cats (13%) with severe" exact="disease" post="died or were euthanized, a fifth cat died after"/>
 <result pre="to 4Â mg/kg daily was required for 5 cats. A" exact="total" post="of 25 treated cats (81%) survived FIP for at"/>
 <result pre="is also a promising therapeutic candidate for treatment of alphacoronavirus-related" exact="disease" post="in cats. Most cats in this study had â€œwetâ€�"/>
 <result pre="study with abdominal non-effusive (â€œdryâ€�) FIP, which is a more" exact="chronic" post="condition, and another 4 cats initially had dry FIP"/>
 <result pre="is that it was conducted among animals with naturally-occurring CoV" exact="infection" post="as a field trial, better representing real-world circumstances. 4.3"/>
 <result pre="with intravenous remdesivir under the compassionate use clause after developing" exact="pneumonia" post="in January 2020 [37]. This 35-year-old male had been"/>
 <result pre="the first 12 COVID-19 patients in the U.S. (who had" exact="disease" post="onset between January 14 and 29, 2020) recently became"/>
 <result pre="This report, authored by a team from the Centers for" exact="Disease" post="Control (CDC), described the demographic and clinical characteristics of"/>
 <result pre="of the patients, as well as information on course of" exact="disease" post="and clinical management. Seven of the 12 patients (58%)"/>
 <result pre="in all three patients after administration. Treatment was discontinued after" exact="respiratory" post="symptoms improved (total treatment durations of 4Â days, 5Â"/>
 <result pre="[9]. Interestingly, patients who received remdesivir had slower rates of" exact="viral" post="clearance compared to patients who received single-dose antivirals (specifically,"/>
 <result pre="the potential efficacy of remdesivir specifically against CoVs is largely" exact="limited" post="to in vitro and animal studies, though COVID-19 related"/>
 <result pre="evolving quickly. Overall, past studies on other CoVs may have" exact="limited" post="generalizability to the virus underlying the current pandemic because"/>
 <result pre="With regard to animal models, how closely the model represents" exact="disease" post="pathogenesis and drug metabolism in humans can be challenging"/>
 <result pre="in humans can be challenging to gauge. 4.4 Clinical trials" exact="Multiple" post="clinical trials are underway on the use of remdesivir"/>
 <result pre="per day, through discharge up to a maximum of 10" exact="total" post="treatment days [20]. The primary outcome of the trial,"/>
 <result pre="to a maximum of 10 total treatment days [20]. The" exact="primary" post="outcome of the trial, as described in the U.S."/>
 <result pre="remdesivir study among patients with severe COVID-19 with a composite" exact="primary" post="outcome measure of fever normalization and oxygen normalization [43]."/>
 <result pre="oxygen normalization [43]. Table 2 Ordinal seven-point scale used as" exact="primary" post="outcome in the U.S. National Institutes of Health sponsored"/>
 <result pre="while the other is focused on severe cases [45]. The" exact="primary" post="outcome measure for the study on mild or moderate"/>
 <result pre="to clinical recovery, as defined by normalization of body temperature," exact="respiratory" post="rate, and oxygen saturation, and the resolution of cough"/>
 <result pre="study on severe cases, time to clinical improvement is the" exact="primary" post="outcome and is defined using a six-category scale, ranging"/>
 <result pre="References 1VassilaraF.SpyridakiA.PothitosG.DeliveliotouA.PapadopoulosA.A rare Case of human coronavirus 229E associated with" exact="acute" post="respiratory distress syndrome in a healthy adultCase Rep. Infect."/>
 <result pre="1VassilaraF.SpyridakiA.PothitosG.DeliveliotouA.PapadopoulosA.A rare Case of human coronavirus 229E associated with acute" exact="respiratory" post="distress syndrome in a healthy adultCase Rep. Infect. Dis.20182018679683929850307"/>
 <result pre="Case of human coronavirus 229E associated with acute respiratory distress" exact="syndrome" post="in a healthy adultCase Rep. Infect. Dis.20182018679683929850307 2PaulesC.I.MarstonH.D.FauciA.S.Coronavirus infections-more"/>
 <result pre="infections-more than just the common coldJAMA2020 3World Health OrganizationSARS (Severe" exact="Acute" post="Respiratory Syndrome)Available from:https://www.who.int/ith/diseases/sars/en/(accessed on 9 March 2020) 4World Health"/>
 <result pre="than just the common coldJAMA2020 3World Health OrganizationSARS (Severe Acute" exact="Respiratory" post="Syndrome)Available from:https://www.who.int/ith/diseases/sars/en/(accessed on 9 March 2020) 4World Health OrganizationMiddle"/>
 <result pre="Syndrome)Available from:https://www.who.int/ith/diseases/sars/en/(accessed on 9 March 2020) 4World Health OrganizationMiddle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV): MERS Monthly Summary, November 2019Available from:https://www.who.int/emergencies/mers-cov/en/(accessed"/>
 <result pre="from:https://www.who.int/ith/diseases/sars/en/(accessed on 9 March 2020) 4World Health OrganizationMiddle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV): MERS Monthly Summary, November 2019Available from:https://www.who.int/emergencies/mers-cov/en/(accessed on"/>
 <result pre="2019Available from:https://www.who.int/emergencies/mers-cov/en/(accessed on 9 March 2020) 5MullerM.A.MeyerB.CormanV.M.Al-MasriM.TurkestaniA.RitzD.Presence of Middle East" exact="respiratory" post="syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional,"/>
 <result pre="from:https://www.who.int/emergencies/mers-cov/en/(accessed on 9 March 2020) 5MullerM.A.MeyerB.CormanV.M.Al-MasriM.TurkestaniA.RitzD.Presence of Middle East respiratory" exact="syndrome" post="coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological"/>
 <result pre="with a highly divergent RNA dependent RNA polymeraseAntivir. Res.169201910454131233808 13AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio922018 14MurphyB.G.PerronM.MurakamiE.BauerK.ParkY.EckstrandC.The nucleoside analog GS-441524"/>
 <result pre="the proofreading exoribonucleasemBio922018 14MurphyB.G.PerronM.MurakamiE.BauerK.ParkY.EckstrandC.The nucleoside analog GS-441524 strongly inhibits feline" exact="infectious" post="peritonitis (FIP) virus in tissue culture and experimental cat"/>
 <result pre="proofreading exoribonucleasemBio922018 14MurphyB.G.PerronM.MurakamiE.BauerK.ParkY.EckstrandC.The nucleoside analog GS-441524 strongly inhibits feline infectious" exact="peritonitis" post="(FIP) virus in tissue culture and experimental cat infection"/>
 <result pre="infectious peritonitis (FIP) virus in tissue culture and experimental cat" exact="infection" post="studiesVet. Microbiol.219201822623329778200 15ChoA.SaundersO.L.ButlerT.ZhangL.XuJ.VelaJ.E.Synthesis and antiviral activity of a series"/>
 <result pre="analog GS-441524 for treatment of cats with naturally occurring feline" exact="infectious" post="peritonitisJ. Feline Med. Surg.214201927128130755068 17WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine effectively inhibit"/>
 <result pre="mechanisms of coronavirus cross-species transmissionJ. Virol.84720103134314619906932 28BollesM.DonaldsonE.BaricR.SARS-CoV and emergent coronaviruses:" exact="viral" post="determinants of interspecies transmissionCurr. Opin. Virol.16201162463422180768 29El-SahlyH.M.AtmarR.L.GlezenW.P.GreenbergS.B.Spectrum of clinical"/>
 <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChembiochem.215202073073832022370 31LuR.ZhaoX.LiJ.NiuP.YangB.WuH.Genomic characterisation and epidemiology"/>
 <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChembiochem.215202073073832022370 31LuR.ZhaoX.LiJ.NiuP.YangB.WuH.Genomic characterisation and epidemiology of"/>
 <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChembiochem.215202073073832022370 31LuR.ZhaoX.LiJ.NiuP.YangB.WuH.Genomic characterisation and epidemiology of 2019"/>
 <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirusJ. Biol. Chem.2020 33KirchdoerferR.N.WardA.B.Structure of the SARS-CoV nsp12"/>
 <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirusJ. Biol. Chem.2020 33KirchdoerferR.N.WardA.B.Structure of the SARS-CoV nsp12 polymerase"/>
 <result pre="strains in FranceJ. Gen. Virol.87Pt 1120063349335317030869 35WoganL.Legal Treatment for Cat" exact="Disease" post="Known as FIP Still Years AwayAvailable from:https://news.vin.com/VINNews.aspx?articleId=545482019 36PedersenN.C.EckstrandC.LiuH.LeuteneggerC.MurphyB.Levels of"/>
 <result pre="Known as FIP Still Years AwayAvailable from:https://news.vin.com/VINNews.aspx?articleId=545482019 36PedersenN.C.EckstrandC.LiuH.LeuteneggerC.MurphyB.Levels of feline" exact="infectious" post="peritonitis virus in blood, effusions, and various tissues and"/>
 <result pre="as FIP Still Years AwayAvailable from:https://news.vin.com/VINNews.aspx?articleId=545482019 36PedersenN.C.EckstrandC.LiuH.LeuteneggerC.MurphyB.Levels of feline infectious" exact="peritonitis" post="virus in blood, effusions, and various tissues and the"/>
 <result pre="in blood, effusions, and various tissues and the role of" exact="lymphopenia" post="in disease outcome following experimental infectionVet. Microbiol.1752â€&quot;4201515716625532961 37HolshueM.L.DeBoltC.LindquistS.LofyK.H.WiesmanJ.BruceH.First Case"/>
 <result pre="effusions, and various tissues and the role of lymphopenia in" exact="disease" post="outcome following experimental infectionVet. Microbiol.1752â€&quot;4201515716625532961 37HolshueM.L.DeBoltC.LindquistS.LofyK.H.WiesmanJ.BruceH.First Case of 2019"/>
 <result pre="J. Med.38210202092993632004427 38The COVID-19 Investigation TeamFirst 12 Patients with Coronavirus" exact="Disease" post="2019 (COVID-19) in the United StatesPreprint2020 39MulanguS.DoddL.E.DaveyR.T.Jr.Tshiani MbayaO.ProschanM.MukadiD.A randomized,"/>
 <result pre="United StatesPreprint2020 39MulanguS.DoddL.E.DaveyR.T.Jr.Tshiani MbayaO.ProschanM.MukadiD.A randomized, controlled trial of ebola virus" exact="disease" post="therapeuticsN. Engl. J. Med.3812420192293230331774950 40YangH.XieW.XueX.YangK.MaJ.LiangW.Design of wide-spectrum inhibitors targeting"/>
 <result pre="Safety and Antiviral Activity of Remdesivir (GS-5734â&quot;¢) in Participants With" exact="Severe" post="Coronavirus Disease (COVID-19)Available from:https://clinicaltrials.gov/ct2/show/NCT04292899(accessed on 13 March 2020) 44U.S."/>
 <result pre="Antiviral Activity of Remdesivir (GS-5734â&quot;¢) in Participants With Severe Coronavirus" exact="Disease" post="(COVID-19)Available from:https://clinicaltrials.gov/ct2/show/NCT04292899(accessed on 13 March 2020) 44U.S. National Library"/>
 <result pre="on 14 March 2020) 46BolkerJ.A.Animal models in translational research: Rosetta" exact="stone" post="or stumbling block?Bioessays39122017 47ZhangQ.WangY.QiC.ShenL.LiJ.Clinical trial analysis of 2019-nCoV therapy"/>
</results>
